JP2024506347A5 - - Google Patents

Info

Publication number
JP2024506347A5
JP2024506347A5 JP2023548591A JP2023548591A JP2024506347A5 JP 2024506347 A5 JP2024506347 A5 JP 2024506347A5 JP 2023548591 A JP2023548591 A JP 2023548591A JP 2023548591 A JP2023548591 A JP 2023548591A JP 2024506347 A5 JP2024506347 A5 JP 2024506347A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical product
product according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016254 external-priority patent/WO2022177835A1/en
Publication of JP2024506347A publication Critical patent/JP2024506347A/ja
Publication of JP2024506347A5 publication Critical patent/JP2024506347A5/ja
Pending legal-status Critical Current

Links

JP2023548591A 2021-02-16 2022-02-14 Gdc-9545およびイパタセルチブを含む併用療法を使用する乳がんの処置 Pending JP2024506347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149947P 2021-02-16 2021-02-16
US63/149,947 2021-02-16
PCT/US2022/016254 WO2022177835A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Publications (2)

Publication Number Publication Date
JP2024506347A JP2024506347A (ja) 2024-02-13
JP2024506347A5 true JP2024506347A5 (cg-RX-API-DMAC7.html) 2025-02-18

Family

ID=80682672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548591A Pending JP2024506347A (ja) 2021-02-16 2022-02-14 Gdc-9545およびイパタセルチブを含む併用療法を使用する乳がんの処置

Country Status (6)

Country Link
US (1) US20230381156A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294393A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506347A (cg-RX-API-DMAC7.html)
CN (1) CN116847839A (cg-RX-API-DMAC7.html)
TW (1) TWI881203B (cg-RX-API-DMAC7.html)
WO (1) WO2022177835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
EA201992852A1 (ru) * 2017-06-02 2020-03-27 Одонейт Терапьютикс, Инк. Схема дозирования тезетаксела и капецитабина
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
AU2019321588C1 (en) * 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3897612A1 (en) * 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor

Similar Documents

Publication Publication Date Title
JP2022544485A5 (cg-RX-API-DMAC7.html)
JP2024015120A5 (cg-RX-API-DMAC7.html)
JP2022531898A5 (cg-RX-API-DMAC7.html)
JP2018184465A5 (cg-RX-API-DMAC7.html)
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2018035162A5 (cg-RX-API-DMAC7.html)
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
JP2019508476A5 (cg-RX-API-DMAC7.html)
JP2024533423A5 (cg-RX-API-DMAC7.html)
JP2024530189A5 (cg-RX-API-DMAC7.html)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2023175688A5 (cg-RX-API-DMAC7.html)
JP2024102045A5 (cg-RX-API-DMAC7.html)
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2024506385A5 (cg-RX-API-DMAC7.html)
JP2022543679A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2019513706A5 (cg-RX-API-DMAC7.html)
JP2011506607A5 (cg-RX-API-DMAC7.html)
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
JP2021503448A5 (cg-RX-API-DMAC7.html)
AU2017251804A1 (en) Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer
JP2024540044A5 (cg-RX-API-DMAC7.html)